Rapid Spread of Drug-Resistant Candida auris in European Hospitals

A recent European health survey has raised alarms about the aggressive dissemination of Candida auris, a highly drug-resistant fungus, across hospitals in the continent. Since its initial discovery in 2009, C. auris has expanded into over 40 countries, causing concerning outbreaks and persistent infections. This yeast species, which belongs to the fungi kingdom, can sometimes cause mild infections, but it poses a severe threat to immunocompromised individuals. When it breaches the skin barrier and enters the bloodstream or vital organs, it can lead to life-threatening conditions. Mortality rates due to invasive C. auris infections range from 30% to 60%, and its ability to resist multiple antifungal drugs complicates treatment efforts. The fungus’s resilience is compounded by its rapid evolution into resistant strains, with some no longer responding to any available medications. C. auris primarily transmits within hospitals through contact with infected patients or contaminated surfaces. Its capability to adhere to surfaces via specialized proteins called adhesins makes eradication difficult. The challenge in controlling its spread is intensified by diagnostics that often misidentify C. auris as common yeasts, delaying appropriate responses. Its optimal growth at elevated temperatures and resistance to routine disinfection allow it to thrive in warm hospital environments and form stubborn biofilms. Europe has experienced a swift increase in cases, with over 4,000 reported between 2013 and 2023, including more than 1,300 in 2023 alone. The UK observed a 23% rise in cases over six months, emphasizing the urgency to implement strict infection control measures. Public health agencies are actively advocating for enhanced surveillance, early detection, and responsible use of antifungal medications. Experts agree that swift intervention during initial outbreaks can contain or even prevent widespread endemicity. However, once C. auris becomes entrenched in healthcare settings, controlling its growth becomes an uphill battle. To combat this emerging threat, hospitals and governments must adopt comprehensive strategies that include strict hygiene protocols, reporting of cases, and investment in specialized testing. Without decisive action, C. auris could establish itself as a permanent menace in healthcare environments, leading to increased infections, costs, and mortality. The emergence of strains resistant to all major antifungal drugs underlines the critical need for continued research and global collaboration to develop effective countermeasures.

source: https://medicalxpress.com/news/2025-09-deadly-drug-resistant-fungus-rapidly.html